SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biopharmaceutical company, has announced the commencement of a Phase 1 clinical trial for F230, targeting pulmonary arterial hypertension (PAH). The first volunteer has been successfully dosed in this trial, which aims to evaluate the safety, tolerability, and pharmacokinetics of F230 in healthy volunteers. This trial signifies Gyre's expansion into the PAH field, a condition with limited treatment options. F230, a novel endothelin A receptor antagonist, is designed to mitigate pulmonary vascular remodeling and reduce pulmonary pressure. Results from this Phase 1 trial have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。